GSK Aktie

46,80 EUR +0,20 EUR +0,43 %

07:05:03

STU

53,78 USD +0,39 USD +0,72 %

16.03.2026

BTT

GSK jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.93,05 Mrd. EUR

KGV13,19Div. Rendite3,58%

WKNA3DMHS

ISINUS37733W2044

SymbolGSK

GSK Aktien News

Sortieren:Datum Meistgelesen

03.09.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK

27.08.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK

22.08.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK

WerbungGSK-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

16.08.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK

31.07.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK

28.07.25PR NewswireHengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

27.07.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK

02.06.25PR NewswireTheravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

07.04.25PR NewswireGSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit with the Schall Law Firm

31.03.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK

28.03.25PR NewswireGSK Deadline: GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit

27.03.25PR NewswireThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in GSK plc Lawsuit - GSK

26.03.25PR NewswireViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program

17.03.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK

07.03.25PR NewswireLevi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of GSK plc(GSK) Shareholders

04.03.25PR NewswireGSK plc Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - GSK

03.03.25PR NewswireGSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit

28.02.25PR NewswireGSK plc Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - GSK

26.02.25PR NewswireGSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit

25.02.25PR NewswireGSK plc. (GSK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

16.02.25PR NewswireGSK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that GSK plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

14.02.25PR NewswireShareholders of GSK plc Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - GSK

13.02.25PR NewswireViiV Healthcare and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully finalize negotiations for APRETUDE for HIV-1 Pre-Exposure Prophylaxis

07.02.25PR NewswireGSK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that GSK plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

06.02.25PR NewswireGSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit

31.07.24PR NewswireViiV Healthcare announces positive data demonstrating 2-drug regimen DOVATO is as effective as 3-drug regimen BIKTARVY for maintenance therapy of HIV-1

28.06.23PR NewswireStock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health

28.03.23PR NewswirePhase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab-gxly) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemother...

GSK News

GSK News: auf dieser Seite finden Sie alle GSK News und Nachrichten zur GSK Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch GSK News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um GSK News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.